The approval was backed by Abbott’s Distinct study, which is the largest randomized controlled trial for spinal cord stimulation in chronic back pain patients who are ineligible for surgery, according to a news release. The study followed 270 patients and found that 91.4 percent of those recieving spinal cord stimulation saw significant pain relief or improved function.
The indication will span across Abbott’s entire spinal cord stimulator portfolio including the recharge-free Proclaim and rechargable Eterna.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
